NO20063254L - Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist - Google Patents

Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist

Info

Publication number
NO20063254L
NO20063254L NO20063254A NO20063254A NO20063254L NO 20063254 L NO20063254 L NO 20063254L NO 20063254 A NO20063254 A NO 20063254A NO 20063254 A NO20063254 A NO 20063254A NO 20063254 L NO20063254 L NO 20063254L
Authority
NO
Norway
Prior art keywords
toll
receptor
agonist
immunostimulatory composition
composition
Prior art date
Application number
NO20063254A
Other languages
English (en)
Inventor
Jean Haensler
Nicolas Burdin
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of NO20063254L publication Critical patent/NO20063254L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen vedrører en immunstimulerende sammensetning omfattende minst en Toll- lignende reseptor 7 eller Toll-Ugnende reseptor 8 agonist og en Toll-hgnende reseptor 4 agonist. Den oppfirmeriske sammensetningen kan også omfatte et vaksineantigen.
NO20063254A 2003-12-19 2006-07-13 Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist NO20063254L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0314995A FR2863890B1 (fr) 2003-12-19 2003-12-19 Composition immunostimulante
PCT/FR2004/003308 WO2005060966A1 (fr) 2003-12-19 2004-12-20 Composition immunostimulante comprenant au moins un agoniste des recepteurs toll-like 7 ou du recepteur toll-like 8 et un agoniste du recepteur toll-like 4

Publications (1)

Publication Number Publication Date
NO20063254L true NO20063254L (no) 2006-07-13

Family

ID=34630344

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063254A NO20063254L (no) 2003-12-19 2006-07-13 Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist

Country Status (14)

Country Link
US (2) US20070087009A1 (no)
EP (1) EP1750707B1 (no)
JP (1) JP2007514725A (no)
KR (1) KR20060124669A (no)
CN (1) CN1921862A (no)
AU (1) AU2004305276B2 (no)
BR (1) BRPI0417192A (no)
CA (1) CA2549114C (no)
FR (1) FR2863890B1 (no)
IL (1) IL176270A0 (no)
LV (1) LV13498B (no)
NO (1) NO20063254L (no)
WO (1) WO2005060966A1 (no)
ZA (1) ZA200605250B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070114727A (ko) 2005-01-28 2007-12-04 갈렌바이오 인코포레이티드 면역학적 활성 조성물
KR101205064B1 (ko) * 2005-04-26 2012-11-27 에자이 알앤드디 매니지먼트 가부시키가이샤 암 면역요법을 위한 조성물과 방법
WO2007024707A2 (en) * 2005-08-22 2007-03-01 The Regents Of The University Of California Tlr agonists
CA2636424A1 (en) * 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agonists for vaccines and tumor immunotherapy
US8846697B2 (en) 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
HUE032422T2 (en) 2006-09-29 2017-09-28 Takeda Vaccines Inc Norovirus vaccine preparations
WO2008115319A2 (en) 2007-02-07 2008-09-25 Regents Of The University Of California Conjugates of synthetic tlr agonists and uses therefor
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CA2698397C (en) 2007-09-18 2018-03-27 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
EP2259788A4 (en) * 2008-02-07 2011-03-16 Univ California TREATMENT OF BLADDER DISEASES WITH A TLR7 ACTIVATOR
EP2303236A4 (en) * 2008-07-01 2012-09-26 Univ Emory SYNERGISTIC INDUCTION OF HUMOR AND CELLULAR IMMUNITY BY COMBINATORY ACTIVATION OF TOLL-LIKE RECEPTORS
CN104911154A (zh) 2008-08-08 2015-09-16 武田疫苗股份有限公司 交叉反应性增强的包含复合衣壳氨基酸序列的病毒样颗粒
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
CA2752074A1 (en) 2009-02-11 2010-08-19 The Regents Of The University Of California Toll-like receptor modulators and treatment of diseases
DK2575876T3 (en) * 2010-05-26 2018-03-12 Selecta Biosciences Inc MULTIVALENT VACCINES WITH SYNTHETIC NANO CARRIERS
JP6208659B2 (ja) 2011-07-11 2017-10-04 タケダ ワクチン,インコーポレイテッド 非経口ノロウイルスワクチン製剤
TWI687434B (zh) 2014-10-07 2020-03-11 日商賽多利克公司 使用來自hsp70之胜肽之用於治療或預防癌之醫藥組成物、免疫誘導劑、及抗原呈現細胞之製造方法
TW202115102A (zh) 2015-03-09 2021-04-16 日商賽多利克公司 來自gpc3之胜肽、使用此胜肽之用於治療或預防癌症之醫藥組成物、免疫誘導劑、及抗原呈現細胞之製造方法
BR112017020404A2 (pt) * 2015-04-07 2018-07-10 Cytlimic Inc. medicamento
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
EP3527216B1 (en) 2016-10-11 2024-02-14 NEC Corporation A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide
US10508115B2 (en) * 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
KR100711561B1 (ko) * 1999-02-01 2007-04-27 에-자이가부시기가이샤 면역학적 보조제 화합물
US20030139364A1 (en) * 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
DE60230340D1 (de) * 2001-11-16 2009-01-22 3M Innovative Properties Co N-Ä4-(4-Amino-2-ethyl-1H-imidazoÄ4,5-cÜchinolin-1-yl)butylÜmethanesulfonamide, diese enthaltende pharmazeutische Zusammensetzung und deren Verwendung
NZ573064A (en) * 2002-04-04 2011-02-25 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
US20040248837A1 (en) * 2002-11-01 2004-12-09 Eyal Raz Methods of treating pulmonary fibrotic disorders
CA2511538C (en) * 2002-12-30 2013-11-26 3M Innovative Properties Company Immunostimulatory combinations
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
CN101022827A (zh) * 2004-06-30 2007-08-22 魁北克益得生物医学公司 用于治疗冠状病毒感染的疫苗组合物

Also Published As

Publication number Publication date
IL176270A0 (en) 2006-10-05
FR2863890B1 (fr) 2006-03-24
JP2007514725A (ja) 2007-06-07
WO2005060966A1 (fr) 2005-07-07
ZA200605250B (en) 2007-11-28
US20100247557A1 (en) 2010-09-30
LV13498B (en) 2007-05-20
FR2863890A1 (fr) 2005-06-24
CN1921862A (zh) 2007-02-28
AU2004305276B2 (en) 2010-07-01
KR20060124669A (ko) 2006-12-05
EP1750707B1 (fr) 2018-03-14
AU2004305276A1 (en) 2005-07-07
EP1750707A1 (fr) 2007-02-14
BRPI0417192A (pt) 2007-03-06
CA2549114A1 (en) 2005-07-07
US20070087009A1 (en) 2007-04-19
CA2549114C (en) 2013-05-14

Similar Documents

Publication Publication Date Title
NO20063254L (no) Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist
CY2019029I1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
DK1718677T3 (da) Monovalente antistoffragmenter egnede som terapeutiske midler
DK1545597T3 (da) Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
CY1113020T1 (el) Εμβολια συνδυασμου για neisseria meningitidis
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
NO20055018D0 (no) Anti-amyolide antistoffer, sammensetninger, fremgangsmater og anvendelser
ATE426412T1 (de) Adjuvante influenza-vakzine
CY2014038I1 (el) Αντι-il-6 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
LTPA2018502I1 (lt) Per burną vartojamos kladribino kompozicijos
CY1109649T1 (el) Αντιγονα και συνθεσεις απο neisseria
NO20055568D0 (no) Substituerte 1,4-diazepiner og anvendelser derav
CY1106431T1 (el) Γονοκοκκικες πρωτεϊνες και νουκλεϊκα οξεα
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
CY1107451T1 (el) Υδροβρωμικον escitalopram και μεθοδος δια την παρασκευη αυτου
CY1108526T1 (el) Εμβολια εναντι καρκινων
DE60226175D1 (de) Mycobakterieller impfstoff
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
JP2005503339A5 (no)
ATE414540T1 (de) Impfstoffe gegen allergien
IL193391A0 (en) Influenza antigens, vaccine compositions, and related methods

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application